GDTC · CytoMed Therapeutics Limited

This filing discloses a binding private share purchase agreement between CytoMed Therapeutics Limited’s Chairman and Director, Choo Chee Kong, and an independent arm’s-length shareholder. The agreement resulted in Mr. Choo acquiring 112,000 ordinary shares for cash — a transaction conducted outside the Company’s involvement and without any proceeds flowing to the issuer. While not a corporate action, the disclosure is material because it signals increased insider ownership by the Chairman, who also explicitly indicated intent to pursue further similar purchases. Such transactions may influence investor perception of management’s confidence in the company’s prospects, though the filing contains no commentary on strategy, valuation, or future plans beyond the stated intent to acquire more shares. Because the transaction involves a senior executive, is definitive and binding, and relates to equity ownership that could affect voting control or market sentiment, it meets the threshold for Item 1.01 (Material Definitive Agreement) under SEC rules for foreign private issuers. No financial terms beyond the share count and cash consideration are disclosed, and no regulatory approvals, conditions, or timelines beyond the May 13, 2026 execution date are provided.